Moderator
William V Padula, PhD, University of Southern California, Rancho Palos Verdes, CA, United States
Speakers
Jaime Rubin Cahill, BA, MA, MPH, Vertex Pharmaceuticals, Inc., boston, MA, United States; Dave McLean, Emerging Therapy Solutions, Bloomington, MN, United States; Jon Blum, USC Schaeffer Institute, Los Angeles, CA, United States; Brett Kopelan, Debra of America, Boulder, CO, United States
Breakthrough gene therapies are transforming the outlook for patients with devastating diseases such as sickle cell disease and spinal muscular atrophy, offering the possibility of a one-time, curative treatment. But with price tags often exceeding $2 million per patient, these therapies pose an existential challenge for insurers, Medicaid programs, and employers — many of whom acknowledge that widespread use at current prices could destabilize their budgets.
This session confronts one of the most urgent investment questions of the decade: How do we finance a pipeline of curative therapies without collapsing the system that pays for them? Drawing on the models highlighted in the article — including long-term amortization (“mortgage-style”) financing, risk-pooling innovations, and public–private partnerships — panelists will explore which payment structures are viable, scalable, and investable.
Topic
Health Technology Assessment